MammaPrint Index as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2- breast cancer in NBRST.
Beitsch P, Pellicane J, Pusztai L, Baron P, Cobain E, Murray M, Ashikari A, Kelemen P, Mislowsky A, Barone J, Cowan K, Layeequr Rahman R, Dooley W, Menicucci A, Finn C, Audeh M, Whitworth P. MammaPrint Index as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2- breast cancer in NBRST. Journal Of Clinical Oncology 2023, 41: 521-521. DOI: 10.1200/jco.2023.41.16_suppl.521.Peer-Reviewed Original ResearchDistant metastasis-free survivalPathological complete responseNeoadjuvant chemotherapyHigh riskGrade 3 tumorsLymph node statusObservational prospective studyHigh-risk tumorsKaplan-Meier analysisStage breast cancerLog-rank testPrediction of chemosensitivityESBC patientsMammaPrint testSYMPHONY trialsFree survivalNeoadjuvant therapyClinicopathologic subtypesComplete responseDistant metastasisImmune therapyMeier analysisRisk tumorsNode statusProspective study